vs
林德（LIN）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是林德的1.0倍（$9.1M vs $8.8M），林德同比增速更快（8.2% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $898.0K），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -96.7%）
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
LIN vs PLX — 直观对比
营收规模更大
PLX
是对方的1.0倍
$8.8M
营收增速更快
LIN
高出58.2%
-49.9%
自由现金流更多
PLX
多$729.0K
$898.0K
两年增速更快
PLX
近两年复合增速
-96.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.8M | $9.1M |
| 净利润 | — | $-5.5M |
| 毛利率 | 48.5% | 49.4% |
| 营业利润率 | 27.8% | -51.1% |
| 净利率 | — | -60.3% |
| 营收同比 | 8.2% | -49.9% |
| 净利润同比 | — | -184.8% |
| 每股收益（稀释后） | $3.98 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LINPLX
| Q1 26 | $8.8M | — | ||
| Q4 25 | $8.8B | $9.1M | ||
| Q3 25 | $8.6B | $17.9M | ||
| Q2 25 | $8.5B | $15.7M | ||
| Q1 25 | $8.1B | $10.1M | ||
| Q4 24 | $8.3B | $18.2M | ||
| Q3 24 | $8.4B | $18.0M | ||
| Q2 24 | $8.3B | $13.5M |
净利润LINPLX
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $-5.5M | ||
| Q3 25 | $1.9B | $2.4M | ||
| Q2 25 | $1.8B | $164.0K | ||
| Q1 25 | $1.7B | $-3.6M | ||
| Q4 24 | $1.7B | $6.5M | ||
| Q3 24 | $1.6B | $3.2M | ||
| Q2 24 | $1.7B | $-2.2M |
毛利率LINPLX
| Q1 26 | 48.5% | — | ||
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% |
营业利润率LINPLX
| Q1 26 | 27.8% | — | ||
| Q4 25 | 23.0% | -51.1% | ||
| Q3 25 | 27.5% | 11.9% | ||
| Q2 25 | 27.7% | 7.5% | ||
| Q1 25 | 26.9% | -41.0% | ||
| Q4 24 | 27.4% | 39.6% | ||
| Q3 24 | 25.0% | 22.2% | ||
| Q2 24 | 26.4% | -18.0% |
净利率LINPLX
| Q1 26 | — | — | ||
| Q4 25 | 17.5% | -60.3% | ||
| Q3 25 | 22.4% | 13.2% | ||
| Q2 25 | 20.8% | 1.0% | ||
| Q1 25 | 20.6% | -35.8% | ||
| Q4 24 | 20.8% | 35.6% | ||
| Q3 24 | 18.5% | 18.0% | ||
| Q2 24 | 20.1% | -16.4% |
每股收益（稀释后）LINPLX
| Q1 26 | $3.98 | — | ||
| Q4 25 | $3.28 | $-0.06 | ||
| Q3 25 | $4.09 | $0.03 | ||
| Q2 25 | $3.73 | $0.00 | ||
| Q1 25 | $3.51 | $-0.05 | ||
| Q4 24 | $3.61 | $0.10 | ||
| Q3 24 | $3.22 | $0.03 | ||
| Q2 24 | $3.44 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.0M | $14.7M |
| 总债务越低越好 | $24.7M | — |
| 股东权益账面价值 | $40.1M | $48.2M |
| 总资产 | $86.3M | $82.3M |
| 负债/权益比越低杠杆越低 | 0.62× | — |
8季度趋势，按日历期对齐
现金及短期投资LINPLX
| Q1 26 | $4.0M | — | ||
| Q4 25 | $5.1B | $14.7M | ||
| Q3 25 | $4.5B | $13.6M | ||
| Q2 25 | $4.8B | $17.9M | ||
| Q1 25 | $5.3B | $19.5M | ||
| Q4 24 | $4.8B | $19.8M | ||
| Q3 24 | $5.2B | $27.4M | ||
| Q2 24 | $4.6B | $23.4M |
总债务LINPLX
| Q1 26 | $24.7M | — | ||
| Q4 25 | $20.7B | — | ||
| Q3 25 | $18.6B | — | ||
| Q2 25 | $19.7B | — | ||
| Q1 25 | $17.6B | — | ||
| Q4 24 | $15.3B | — | ||
| Q3 24 | $17.5B | — | ||
| Q2 24 | $16.9B | — |
股东权益LINPLX
| Q1 26 | $40.1M | — | ||
| Q4 25 | $38.2B | $48.2M | ||
| Q3 25 | $38.6B | $52.9M | ||
| Q2 25 | $38.5B | $49.9M | ||
| Q1 25 | $38.0B | $45.2M | ||
| Q4 24 | $38.1B | $43.2M | ||
| Q3 24 | $39.2B | $32.4M | ||
| Q2 24 | $38.2B | $28.6M |
总资产LINPLX
| Q1 26 | $86.3M | — | ||
| Q4 25 | $86.8B | $82.3M | ||
| Q3 25 | $86.0B | $82.3M | ||
| Q2 25 | $86.1B | $78.5M | ||
| Q1 25 | $82.7B | $73.9M | ||
| Q4 24 | $80.1B | $73.4M | ||
| Q3 24 | $82.5B | $61.6M | ||
| Q2 24 | $80.2B | $91.5M |
负债/权益比LINPLX
| Q1 26 | 0.62× | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $898.0K | $1.6M |
| 自由现金流率自由现金流/营收 | 10.2% | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $4.2B | $-13.6M |
8季度趋势，按日历期对齐
经营现金流LINPLX
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $2.0M | ||
| Q3 25 | $2.9B | $-3.7M | ||
| Q2 25 | $2.2B | $-5.2M | ||
| Q1 25 | $2.2B | $-5.1M | ||
| Q4 24 | $2.8B | $4.0M | ||
| Q3 24 | $2.7B | $4.1M | ||
| Q2 24 | $1.9B | $-3.6M |
自由现金流LINPLX
| Q1 26 | $898.0K | — | ||
| Q4 25 | $1.6B | $1.6M | ||
| Q3 25 | $1.7B | $-4.2M | ||
| Q2 25 | $954.0M | $-5.7M | ||
| Q1 25 | $891.0M | $-5.4M | ||
| Q4 24 | $1.6B | $3.6M | ||
| Q3 24 | $1.7B | $4.0M | ||
| Q2 24 | $796.0M | $-3.8M |
自由现金流率LINPLX
| Q1 26 | 10.2% | — | ||
| Q4 25 | 17.9% | 17.8% | ||
| Q3 25 | 19.4% | -23.7% | ||
| Q2 25 | 11.2% | -36.2% | ||
| Q1 25 | 11.0% | -53.0% | ||
| Q4 24 | 18.8% | 19.6% | ||
| Q3 24 | 19.9% | 22.4% | ||
| Q2 24 | 9.6% | -28.1% |
资本支出强度LINPLX
| Q1 26 | — | — | ||
| Q4 25 | 16.6% | 4.4% | ||
| Q3 25 | 14.8% | 2.8% | ||
| Q2 25 | 14.8% | 2.8% | ||
| Q1 25 | 15.7% | 3.0% | ||
| Q4 24 | 15.1% | 2.3% | ||
| Q3 24 | 12.8% | 0.5% | ||
| Q2 24 | 13.7% | 1.3% |
现金转化率LINPLX
| Q1 26 | — | — | ||
| Q4 25 | 1.98× | — | ||
| Q3 25 | 1.53× | -1.58× | ||
| Q2 25 | 1.25× | -31.91× | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.63× | 0.61× | ||
| Q3 24 | 1.76× | 1.27× | ||
| Q2 24 | 1.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LIN
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
